Agomab receives FDA Orphan Drug Designation for AGMB-447 in idiopathic pulmonary fibrosis BusinessWire Jun 6, 2024 AGMB-447 is an inhaled lung-restricted ALK5-inhibitor currently in a Phase 1 clinical trial Agomab Therapeutics announced that…
